The Future of Cell & Gene Therapy Spearheading the Next Wave of In Vivo Therapies by Optimizing Target Specificity, Advancing Delivery Technologies & Showcasing In-Human Clinical Validation to Global Regulators
The in vivo cell engineering and gene editing landscape is entering a pivotal moment as investment from leaders such as Kite Pharma, Eli Lilly, AstraZeneca, and AbbVie accelerates and reshapes the competitive landscape. With ex vivo approaches facing high costs, long turnaround times, and conditioning burdens, developers are moving rapidly toward in vivo therapies that offer greater accessibility, faster clinical timelines, and broader therapeutic reach. The momentum is reinforced by emerging innovators securing significant funding, including recent successes such as Azalea Therapeutics.
Returning to Boston, the 5th In Vivo Cell Engineering & Gene Editing Summit is the only meeting dedicated entirely to advancing targeted in vivo delivery, early clinical validation, and global development strategy. This year introduces a new spotlight on in vivo development in Asia, reflecting the industry’s growing interest in fast‑moving investigator-initiated trials, regional manufacturing capacity, and rapidly emerging clinical datasets.
Across three days, attendees will benchmark their programs against leading developers, collaborate with experts across delivery, editing, CMC, and clinical development, and expand their networks to include new partners across the US, Europe, and Asia. This is the definitive platform for teams determined to progress their in vivo pipeline, accelerate IND‑enabling work, and stay ahead as the field enters its next wave of growth.
The field is maturing and evolving rapidly and what was once thought to be impossible is now trending mainstream. This conference leads the way and continues to highlight the most innovative and practical approaches to in vivo gene editing.
Eric Kmiec, Founder & Chief Scientific Officer, CorriXR Therapeutics
In vivo CAR-T cell therapies have shown strong clinical responses in early stage trials; I'm excited to share our work that could help further advance this approach.
Matt Spindler, Vice President, Research, GigaMune
The rapid growth in the field means that the 5th In Vivo Cell Engineering & Gene Editing Summit is now one of the most important events to hear from the leaders in the space where this field is and where it is going.”
Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Explore the Full Program
- 20+ world‑class speakers shaping the future of in vivo
- New “Spotlight on Asia” workshop featuring frontline clinical and manufacturing insights
- In‑depth delivery comparisons across LNP, VLP, LVV, and non‑viral systems
- Exclusive first‑in‑human and translational data presentations
- Dedicated networking, including the "Partner‑sips" Mixer and Poster Showcase
Official Partners
Attending Companies Include
Explore Related Events
Explore the Full Program
View the detailed agenda, featured speakers, session highlights, and networking opportunities shaping the fastest‑growing frontier in cell and gene therapy.
Secure Your Place
Join the only meeting dedicated to accelerating in vivo cell engineering and gene editing. Connect with global leaders, access exclusive clinical insights for first-in-human trials, and strengthen your development and delivery strategies.
Showcase Your Capabilities
Position your organization in front of senior R&D and CMC decision-makers at the forefront of this growing field. Attendees are seeking CDMOs, CROs, and vector design expertise to scale their in vivo programs.